|
THIS MONTH IN SKIN CANCER
Evidence from ongoing trials will reveal the optimal approach to combining immune therapy and molecularly targeted therapy in the treatment of malignant melanoma, according to a presenter here at the 8th Canadian melanoma conference. » Read more
|
|
Although melanoma and non-melanoma skin cancers such as basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are more prevalent in Caucasian skin, patients with darker Fitzpatrick Skin Types are also at risk of developing skin cancers, underscoring the importance for this patient population to practice appropriate photoprotection. » Read more
|
|
Gene expression profiling with a commercially available test (DecisionDx-Melanoma, Castle Biosciences) provides useful prognostic information for patients with high-risk cutaneous melanoma who undergo sentinel lymph node (SLN) biopsy, and particularly for those found to be node-negative, according to a study presented at the annual meeting of the American Society for Clinical Oncology. » Read more
|
|
Metastatic melanoma patients treated with sargramostim and ipilimumab experienced longer overall survival and less toxicity than patients treated with ipilimumab alone. » Read more
|
|
Toxicity from some of today’s newer chemotherapeutic agents often emerges on the skin. Dermatologists play an important role in the management of these cutaneous effects and should work with oncologists to cure and prevent them, researchers reported last year in the European Medical Journal Dermatology. » Read more
|
|
|
Like
Tweet
